Emir Cerme

7PUBLICATIONS
27CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersImmunogenetics (incl. genetic immunology)Cancer therapy (excl. chemotherapy and radiation therapy)Nanomedicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 27, 2026
Erythrocyte Transfusion as an Independent Predictor of Survival but Not Immune-Related Toxicity in Nivolumab-Treated Metastatic NSCLC: A Multicenter Cohort.

|Aug 13, 2026
Does the CRP/Albumin Ratio Independently Predict Survival in Metastatic Colorectal Cancer? Insights from a Propensity Score-Matched Cohort.

|May 06, 2026
Immune-Mediated upper gastrointestinal toxicities reported With immune checkpoint inhibitors: An analysis of the food and drug administration adverse event reporting system (FAERS).

|Apr 21, 2026
Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study.

|Dec 30, 2025
Stage II colon cancer: does ChatGPT recommend more intensive adjuvant therapy? A comparison with MDT decisions.

Zeliha Birsin, Seda Jeral, Selin Cebeci

|Aug 17, 2023
Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis.

Didar Ucar, Sinem Nihal Esatoglu, Emir Cerme

Pageof 2

Frequent Collaborators

4 joint publications

Özkan Alan

4 joint publications

Hamza Abbasov

4 joint publications

Murad Guliyev

3 joint publications

Mehmet Cem Fidan